Dr Reddy’s Laboratories Ltd. is preparing to enter the rapidly expanding market for semaglutide in India, with plans to launch a generic version of Ozempic in March following the expiry of Novo Nordisk AS’s patent on 21 March. The move positions the Hyderabad-based pharmaceutical company among the first Indian manufacturers to capitalize on growing demand for weight-loss and diabetes therapies in what is often described as the diabetes capital of the world.
Company executives have described the launch as a major commercial opportunity, signaling the beginning of intensified competition in a market long dominated by Novo Nordisk’s blockbuster franchise. Ozempic, widely used for the treatment of Type 2 diabetes, is part of Novo Nordisk’s $30-billion portfolio, which also includes Wegovy, indicated for weight management. With patent protections ending in India, dozens of domestic and…
